Category: Press Releases

• Researchers with Nauru Ocean Resources Inc. (NORI) successfully gathered further environmental data on ecosystem recovery and functioning as part of its Environmental and Social Impact Assessment (ESIA) to characterise the potential impacts of proposed polymetallic nodule collection operations.
• Despite illegal disruptions from Greenpeace International aimed at hindering the collection of environmental data, researchers were able to complete the major components of the scientific work scope slated for the campaign, and are encouraged by preliminary qualitative assessments.
• Scientists used several seafloor sampling devices, a remotely operated vehicle and lander systems to assess impacts to biota, seafloor geochemistry and ecosystem recovery on the seafloor in the NORI-D area of the Clarion Clipperton Zone (CCZ).
• Building on the rich data gathered from 20 offshore campaigns over the last 11 years, with cumulative ESIA spending of ~$150 million, the results from the latest campaign will inform NORI’s application to the International Seabed Authority (ISA) for a commercial exploitation contract.

NEW YORK, Dec. 28, 2023 (GLOBE NEWSWIRE) — The Metals Company (Nasdaq: TMC) (“TMC” or “the Company”), an explorer of lower-impact battery metals from seafloor polymetallic nodules, today announced the conclusion of its latest offshore scientific research campaign to assess seafloor impacts and recovery rates twelve months after the pilot nodule collection system test conducted by its NORI subsidiary.

Despite illegal disruptions from Greenpeace International aimed at hindering the collection of key environmental data requested by the ISA’s Legal and Technical Commission, researchers were able to complete the major components of the scientific work scope slated for the campaign. The data gathered will further support NORI’s application to the International Seabed Authority for a commercial exploitation contract, which it expects to submit following the July 2024 meeting of the ISA.

The team selected 19 sampling stations in the locality of last year’s nodule collection system test and conducted 39 multicore deployments, recovering 395 individual core samples. These yielded more than 600 subsamples that will be shared with independent researchers from leading marine research institutions for further biological analysis.

Additionally, using a remotely operated vehicle (ROV), the research team deployed innovative seafloor lander systems that are capable of measuring seafloor oxygen fluxes using eddy covariance methods. This resulted in over 600 hours of data acquisition at a maximum deployment depth of 4285m, which NORI believes is the first time these bespoke sensor suites have been deployed at abyssal depths. This data is further supplemented by over one thousand core sub-samples for geochemical analysis.

Multicore on deck

Dr Michael Clarke, TMC’s Environmental Manager, said: “Despite attempts to disrupt our offshore scientific program the data collected is more than sufficient to meet our objectives for the campaign. This new information provides an insight as to the scale of seabed disturbance from nodule collection and how the benthic communities respond over time. Using the data collected during our decade-long research program, we can now conduct a robust, data-driven assessment of the impacts of nodule collection on the marine environment. We look forward to presenting the findings of our studies to the ISA and stakeholders in the coming year.”

Using the ROV, the team gathered over 30 hours of dedicated video footage of the seafloor, with particular focus on sessile organisms. Based upon a preliminary qualitative assessment, organisms identified during NORI’s environmental baseline studies are still present twelve months on in areas that have been influenced by the seafloor plume. This data will be shared with researchers for further analysis.

Researchers also conducted the fourth annual recovery and redeployment of three oceanographic moorings within NORI-D. The sensor payload on the moorings provides insights into the soundscape, regional oceanographic currents, and particulate organic carbon flux in the Eastern CCZ region. This data contributes to the long-term oceanographic time series and importantly will cover the El Niño-Southern Oscillation fluctuations.

Earlier this month, NORI began sharing emerging data on the characteristics of seafloor sediment plumes. In line with its commitment to share this key environmental data with society, NORI also convened a global stakeholder webinar attended by over two hundred people to provide an update on its environmental program [watch here].

NORI’s latest environmental campaign adds to the significant research conducted in the deep sea. Since the late 1960s, over 300 hundred offshore campaigns have been conducted in international waters with over $2 billion invested in environmental baseline and impact studies and technology development, with most of the capital invested by private companies. To address knowledge gaps, governments and contractors like NORI have spent over 9,000 days – the equivalent of almost 25 years – at sea, assessing the deep-sea environment, research and investment which has accelerated significantly since the establishment of the ISA’s exploration regime.

About The Metals Company
The Metals Company is an explorer of lower-impact battery metals from seafloor polymetallic nodules, on a dual mission: (1) supply metals for the global energy transition with the least possible negative impacts on planet and people and (2) trace, recover and recycle the metals we supply to help create a metals commons that can be used in perpetuity. The Company through its subsidiaries holds exploration and commercial rights to three polymetallic nodule contract areas in the Clarion Clipperton Zone of the Pacific Ocean regulated by the International Seabed Authority and sponsored by the governments of Nauru, Kiribati and the Kingdom of Tonga. More information is available at www.metals.co.

Contacts
Media | media@metals.co
Investors | investors@metals.co

Forward Looking Statements 
This press release contains “forward-looking” statements and information within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, TMC’s expectations with respect to the success of its recently completed offshore campaign, the results, outcomes or assessments of the campaign and the data generated during the campaign respectively. The Company may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including, among other things: the Company’s strategies and future financial performance; the International Seabed Authority’s (“ISA”) ability to timely adopt the Mining Code and/or willingness to review and/or approve a plan of work for exploitation under the United Nations Convention on the Laws of the Sea (UNCLOS); the Company’s ability to obtain exploitation contracts or approved plans of work for exploitation for its areas in the Clarion Clipperton Zone; regulatory uncertainties and the impact of government regulation and political instability on the Company’s resource activities; changes to any of the laws, rules, regulations or policies to which the Company is subject, including the terms of the final Mining Code, if any, adopted by ISA and the potential timing thereof; the impact of extensive and costly environmental requirements on the Company’s operations; environmental liabilities; the impact of polymetallic nodule collection on biodiversity in the Clarion Clipperton Zone and recovery rates of impacted ecosystems; the Company’s ability to develop minerals in sufficient grade or quantities to justify commercial operations; the lack of development of seafloor polymetallic nodule deposit; the Company’s ability to successfully enter into binding agreements with Allseas Group S.A. and other parties in which it is in discussions, if any; uncertainty in the estimates for mineral resource calculations from certain contract areas and for the grade and quality of polymetallic nodule deposits; risks associated with natural hazards; uncertainty with respect to the specialized treatment and processing of polymetallic nodules that the Company may recover; risks associated with collective, development and processing operations, including with respect to the development of onshore processing capabilities and capacity and Allseas Group S.A.’s expected development efforts with respect to the Project Zero offshore system; the Company’s dependence on Allseas Group S.A.; fluctuations in transportation costs; fluctuations in metals prices; testing and manufacturing of equipment; risks associated with the Company’s limited operating history, limited cash resources and need for additional financing; risks associated with the Company’s intellectual property; Low Carbon Royalties’ limited operating history and other risks and uncertainties, any of which could cause the Company’s actual results to differ from those contained in the forward-looking statements, that are described in greater detail in the section entitled “Risk Factors” in the Company’s Annual Report on Form 10-K filed with the SEC on March 27, 2023, as updated in our Quarterly Report on Form 10-Q filed with the SEC on August 14, 2023, as well as in other filings the Company may make with the SEC in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements contained herein, whether because of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.

Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/5877b238-6be3-43eb-9f0e-a61dc89f0218
https://www.globenewswire.com/NewsRoom/AttachmentNg/0a25a39c-d391-4bdb-9bd0-15ae4c4bae79

GlobeNewswire Distribution ID 9010244

ความร่วมมือใหม่เพื่อกำหนดทิศทางการอภิปรายเกี่ยวกับการพัฒนาที่ยั่งยืนในโลหะและแร่ธาตุทั่วโลกที่ Future Minerals Forum 2024

เมืองริยาด, ประเทศซาอุดีอาระเบีย, Dec. 28, 2023 (GLOBE NEWSWIRE) — Future Minerals Forum (FMF) ซึ่งมีกำหนดจะจัดขึ้นระหว่างวันที่ 9-11 มกราคม ในเมืองริยาด ประเทศซาอุดีอาระเบีย ได้ประกาศความร่วมมือเชิงกลยุทธ์ใหม่ 3 ประการเพื่อแจ้งให้ทราบถึงการอภิปรายอย่างเป็นทางการระดับโลกเกี่ยวกับแร่ธาตุและบทบาทที่สำคัญของแร่ธาตุเหล่านี้ในการพัฒนาระดับโลกที่ยั่งยืนและความจำเป็นในการเปลี่ยนผ่านไปสู่แหล่งพลังงานใหม่ ความร่วมมือครั้งใหม่กับ CRU Group, Global AI และ Wood Mackenzie จะนำเสนอข่าวกรองทางธุรกิจและข้อมูลเชิงลึกในชุดการศึกษาวิจัยที่จะเผยแพร่ก่อน FMF ความร่วมมือใหม่นี้ส่งเสริมความร่วมมือที่มีอยู่เดิมกับ McKinsey & Company, Payne Institute for Public Policy, Clareo-DPI และ Baker Institute

Wood Mackenzie กำลังเริ่มดำเนินการศึกษาวิจัยที่สำคัญเพื่อกำหนดศักยภาพของภูมิภาคที่มีความสำคัญทางยุทธศาสตร์ เอกสารรายงานอย่างเป็นทางการจะระบุตัวขับเคลื่อนหลักสำหรับการสร้างห่วงโซ่คุณค่าที่ยั่งยืน พร้อมทั้งเน้นย้ำถึงความท้าทายในปัจจุบันที่แร่ธาตุทั่วโลกกำลังเผชิญอยู่ และความท้าทายเหล่านี้ส่งผลกระทบต่ออุตสาหกรรมแร่ธาตุในพื้นที่ที่อุดมด้วยทรัพยากรนี้อย่างไร รายงานฉบับนี้จะทำหน้าที่เป็นแนวทางที่สำคัญสำหรับผู้ถือผลประโยชน์ร่วมโดยการวางรากฐานเพื่อให้สามารถบรรลุเป้าหมายจากความร่วมมือระหว่างภาครัฐและตลาดได้ ขณะที่ภูมิภาคมองหาการระบุและใช้ประโยชน์จากศักยภาพของทรัพยากรเพื่อให้เกิดการเปลี่ยนผ่านไปสู่แหล่งพลังงานได้ดียิ่งขึ้น

Global AI ได้เตรียมการพร้อมที่จะดำเนินการวิเคราะห์ความรู้สึกทั่วโลกอย่างครอบคลุมโดยใช้ปัญญาประดิษฐ์ที่ล้ำสมัย โดยมุ่งเน้นที่การดำเนินการเหมืองแร่และแร่ธาตุทั่วทั้งภูมิภาคที่มีความสำคัญทางยุทธศาสตร์ การวิเคราะห์นี้มุ่งหมายเพื่อให้ความกระจ่างเกี่ยวกับการรับรู้ของสังคมเพื่อให้ข้อมูลที่ใช้สำหรับการอภิปรายเกี่ยวกับบทบาทที่รัฐบาล ภาคเอกชน และภาคประชาสังคมต้องมีส่วนร่วมในการสร้างความมั่นใจว่าสังคมจะยอมรับและสนับสนุนการดำเนินงาน เพื่อให้มั่นใจว่าการดำเนินการเหมืองแร่จะมอบผลประโยชน์ที่จับต้องได้ให้กับชุมชนท้องถิ่นและลดผลกระทบต่อสิ่งแวดล้อมให้เหลือน้อยที่สุด

ในขณะเดียวกัน รายงานของ CRU จะเน้นถึงความเร่งด่วนในการจัดการกับอุปสรรคต่อแร่ธาตุสำคัญเพื่อให้บรรลุเป้าหมายด้านสภาพภูมิอากาศ โดยมุ่งเน้นไปที่ตะวันออกกลาง แอฟริกา และเอเชียกลางในฐานะผู้จัดหาหลักในอนาคต

ข้อมูลเชิงลึกเหล่านี้โดยรวมทั้งหมดสอดคล้องกับพันธกิจของ FMF ในการพัฒนาอุตสาหกรรมแร่ที่ยั่งยืน ทำให้ภูมิภาคที่มีความสำคัญทางยุทธศาสตร์กลายเป็นประเด็นหลักของการปภิปรายเรื่องแร่ธาตุทั่วโลก และกำหนดแนวทางปฏิบัติในการทำเหมืองอย่างมีความรับผิดชอบ FMF เป็นแพลตฟอร์มที่นำโดยรัฐบาลและมีผู้ถือผลประโยชน์ร่วมหลายฝ่าย มีเป้าหมายเพื่อกระตุ้นการอภิปรายระหว่างผู้นำอุตสาหกรรม ผู้กำหนดนโยบาย และผู้ถือผลประโยชน์ร่วมเพื่อขับเคลื่อนความก้าวหน้าไปสู่อนาคตที่ยั่งยืนและเจริญรุ่งเรืองมากขึ้นในการพัฒนาแร่ธาตุ

ติดต่อด้านสื่อ:
Omar Shereen
อีเมล: Omar.Shereen@fleishman.com
มือถือ: +966 50 663 0489

GlobeNewswire Distribution ID 1000906248

Proceeds expected to extend cash runway into H2 2027

VANCOUVER, British Columbia, Dec. 26, 2023 (GLOBE NEWSWIRE) — Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biopharmaceutical company developing novel, multifunctional biotherapeutics, today announced that it had entered into a securities purchase agreement with funds affiliated with EcoR1 Capital, LLC (“EcoR1 Capital”), for the sale of an aggregate of 5,086,521 pre-funded warrants to purchase 5,086,521 shares of common stock, $0.00001 par value per share, in a private placement. Each pre-funded warrant will be exercisable at an exercise price equal to $0.0001 per share, subject to adjustments as provided under the terms of the pre-funded warrant and will be exercisable at any time on or after the closing date, subject to a post-exercise beneficial ownership limitation of 19.99%.

“We are grateful for the ongoing commitment and additional financial support from our largest stockholder, EcoR1 Capital, as we work towards making a meaningful difference for people impacted by difficult-to-treat cancers and other serious diseases” said Kenneth Galbraith, Chair and Chief Executive Officer of Zymeworks. “The proceeds from this transaction allow us to further strengthen our financial position and extend our cash runway ahead of key milestones and events expected in 2024 and 2025.”

The proceeds from this transaction will help to broaden and potentially accelerate the Company’s ‘5 by 5’ research and development strategy, with investigational new drug application filings for ZW171 and ZW191 scheduled for 2024, as well as for use in funding general corporate purposes. Based on the Company’s current operating plan, Zymeworks anticipates that the proceeds from this transaction will now extend its current cash runway into H2 2027.

The aggregate gross proceeds from the offering are expected to be approximately $50 million, before deducting estimated offering expenses. The private placement is expected to close on or about December 28, 2023, subject to the satisfaction of customary closing conditions. The purchase price of $9.8299 for each pre-funded warrant was based on the closing price of $9.83 per share of Company’s common stock on The Nasdaq Stock Market LLC on December 22, 2023.

In addition, the Company has agreed that EcoR1 Capital will have the right, anytime until January 1, 2026, to nominate one of its partners as a member of the board of directors of Zymeworks, subject to specified conditions.

The securities sold in this private placement have not been registered under the Securities Act of 1933, as amended, or state securities laws and may not be offered for sale, sold, transferred, assigned or otherwise disposed of absent registration with the U.S. Securities and Exchange Commission (SEC) or an applicable exemption from the registration requirements. Pursuant to the terms of a registration rights agreement entered into by Zymeworks with the investors, Zymeworks has agreed to file a registration statement with the SEC registering the resale of the shares of common stock issuable upon exercise of the pre-funded warrants.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

Additional details regarding this private placement will be included in a Current Report on Form 8-K to be filed by Zymeworks with the SEC.

About Zymeworks Inc.

Zymeworks Inc. (Nasdaq: ZYME) is a global biotechnology company committed to the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Zymeworks’ mission is to make a meaningful difference for people impacted by difficult-to-treat cancers and other serious diseases. Zymeworks’ complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. Zymeworks engineered and developed zanidatamab, a HER2-targeted bispecific antibody using Zymeworks’ proprietary Azymetric technology. Zymeworks has entered into separate agreements with BeiGene, Ltd. (BeiGene) and Jazz Pharmaceuticals Ireland Limited (Jazz), granting each of BeiGene and Jazz with exclusive rights to develop and commercialize zanidatamab in different territories. Zanidatamab is currently being evaluated in global Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials as a treatment for patients with HER2-expressing cancers. Zymeworks’ next clinical candidate, zanidatamab zovodotin (ZW49), is a HER2-targeted bispecific antibody-drug conjugate (ADC) developed using Zymeworks’ proprietary Azymetric and ZymeLink Auristatin technologies. Zanidatamab zovodotin is being evaluated in a Phase 2 clinical trial for patients with HER2-expressing non-small cell lung cancer. Zymeworks is also advancing a deep pipeline of product candidates based on its experience and capabilities in both ADC and multispecific antibodies (MSAT), including planned IND filings for ZW171 and ZW191 in 2024. In addition to Zymeworks’ wholly owned pipeline, its therapeutic platforms have been further leveraged through strategic partnerships with global biopharmaceutical companies. For information about Zymeworks, visit www.zymeworks.com and follow @ZymeworksInc on X.

Cautionary Note Regarding Forward-Looking Statements

This press release includes “forward-looking statements” or information within the meaning of the applicable securities legislation, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this press release include, but are not limited to, statements regarding the expected closing of the private placement, anticipated receipt and use of proceeds from the private placement, whether the conditions for the closing of the private placement will be satisfied, the filing of a registration statement or final prospectus, as applicable, to register the resale of the shares of common stock issuable upon the exercise of the pre-funded warrants to be issued and sold in the private placement, the anticipated cash runway following closing of the private placement, the timing of anticipated IND filings, and other information that is not historical information. When used herein, words such as “plan”, “believe”, “expect”, “may”, “continue”, “anticipate”, “potential”, “will”, “progress”, and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Zymeworks’ current expectations and various assumptions. Zymeworks believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Zymeworks may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various factors, including, without limitation: whether the conditions for the closing of the private placement will be satisfied; clinical trials may not demonstrate safety and efficacy of any of Zymeworks’ or its collaborators’ product candidates; any of Zymeworks’ or its partners’ product candidates may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable; Zymeworks may not achieve milestones or receive additional payments under its collaborations; the impact of pandemics and other health crises on Zymeworks’ business, research and clinical development plans and timelines and results of operations, including impact on its clinical trial sites, collaborators, and contractors who act for or on Zymeworks’ behalf; inability to maintain or enter into new partnerships or strategic collaborations; regulatory agencies may impose additional requirements or delay the initiation of clinical trials; the impact of new or changing laws and regulations; Zymeworks’ assumptions regarding its cash runway may be incorrect; market conditions; and the other risks described under “Risk Factors” in Zymeworks’ Quarterly Report on Form 10-Q for its quarter ended September 30, 2023 (a copy of which may be obtained at www.sec.gov and www.sedar.com). Although Zymeworks believes that such forward-looking statements are reasonable, there can be no assurance they will prove to be correct. Investors should not place undue reliance on forward-looking statements. The above assumptions, risks and uncertainties are not exhaustive. Forward-looking statements are made as of the date hereof and, except as may be required by law, Zymeworks undertakes no obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances, or to reflect the occurrences of unanticipated events.

Contacts:
Investor Inquiries:
Shrinal Inamdar
Director, Investor Relations
(604) 678-1388
ir@zymeworks.com

Media Inquiries:
Diana Papove
Senior Director, Corporate Communications
(604) 678-1388
media@zymeworks.com

GlobeNewswire Distribution ID 9009538

Copenhagen Infrastructure Partners (CIP), through its Growth Markets Funds II and Energy Transition Fund I, will develop Helax Istmo, a green hydrogen and green maritime fuels project in the Isthmus of Tehuantepec, in Oaxaca, Mexico.

COPENHAGEN, Denmark, Dec. 22, 2023 (GLOBE NEWSWIRE) — Helax Istmo (“Helax”), a wholly owned subsidiary of funds managed by CIP, today signed a Memorandum of Understanding (“MoU”) with the Interoceanic Corridor of the Isthmus of Tehuantepec (“CIIT”) and Mexico’s national Ministry of Navy, the Secretaría de Marina (“Semar”). Under the MoU, the parties agree to collaborate to support the development of a large-scale, integrated renewable energy project in Oaxaca, Mexico. Helax Istmo is projected to produce green hydrogen and green maritime fuels, contributing materially to Mexico’s sustainable development goals, as well as to the decarbonization of the shipping industry globally.

The MOU was signed in the presence of Mexican president Andrés Manuel López Obrador, who has recognized the project’s transformational impact for the Isthmus.

Ole Kjems Sørensen, partner at CIP and co-head of Growth Markets Funds, said: “This MoU showcases our long-term commitment to Mexico through the development of a pioneering project that offers green maritime fuels at scale — a first for the region. We would like to thank the Mexican authorities for their continued interest and support, and we look forward to continuing to engage constructively with national and local stakeholders and further develop Helax.”

Philip Cristiani, partner at CIP and co-head of Energy Transition Fund, commented: “Our Energy Transition Fund is the largest dedicated clean hydrogen fund globally and we are proud to take this promising step forward for Helax together with the Mexican authorities. When fully operational, Helax is ideally placed to cater to the growing demand for green shipping fuels and make a significant contribution to the decarbonization of the global shipping industry.”

The MoU acknowledges that Helax will undergo formal indigenous and social consultations under Mexican law. These are expected to take place in early 2024.

About Copenhagen Infrastructure Partners
Founded in 2012, Copenhagen Infrastructure Partners P/S (CIP) today is the world’s largest dedicated fund manager within greenfield renewable energy investments and a global leader in offshore wind. The funds managed by CIP focus on investments in offshore and onshore wind, solar PV, biomass and energy-from-waste, transmission and distribution, reserve capacity, storage, advanced bioenergy, and Power-to-X.

CIP manages 12 funds and has to date raised approximately EUR 26 billion for investments in energy and associated infrastructure from more than 150 international institutional investors. CIP has approximately 500 employees and 12 offices around the world. For more information, visit www.cip.com

For further information, please contact:

Simon Mehl Augustesen, Chief Communication Officer
Phone: +45 3052 6721
Email: siau@cip.com

Thomas Kønig, Partner – Investor Relations
Phone: +45 7070 5151
Email: tkon@cip.com

GlobeNewswire Distribution ID 1000905813

Turin, 22^nd December 2023. Iveco Group N.V. (EXM: IVG) announces that the Company completed on a daily basis, starting from 18^th December 2023 to 20^th December 2023 the following transactions:

Date	Number of repurchased Common Shares	Average net price (euro)	Total net consideration (euro)
18 December 2023	55,700	7.8789	438,853.65
19 December 2023	55,000	7.9187	435,530.74
20 December 2023	54,356	7.9997	434,833.10
Total	165,056	7.9320	1,309,217.49

With the purchases described above the Company completed the initial tranche up to €55,000,000 of the share buyback program announced on 14^th April 2023, based on the authorization to repurchase up to 10,000,000 Common Shares with a maximum total allocation of €130,000,000, granted by the Annual General Meeting held on the same date.

A comprehensive overview of the details of the above transactions as well as the overall purchases related to the initial tranche of such share buyback program, are available on the Company’s corporate website at the following address: https://www.ivecogroup.com/investors/stock_information/share_buyback.

Iveco Group N.V. (EXM: IVG) is the home of unique people and brands that power your business and mission to advance a more sustainable society. The eight brands are each a major force in its specific business: IVECO, a pioneering commercial vehicles brand that designs, manufactures, and markets heavy, medium, and light-duty trucks; FPT Industrial, a global leader in a vast array of advanced powertrain technologies in the agriculture, construction, marine, power generation, and commercial vehicles sectors; IVECO BUS and HEULIEZ, mass-transit and premium bus and coach brands; IDV, for highly specialised defence and civil protection equipment; ASTRA, a leader in large-scale heavy-duty quarry and construction vehicles; MAGIRUS, the industry-reputed firefighting vehicle and equipment manufacturer; and IVECO CAPITAL, the financing arm which supports them all. Iveco Group employs more than 35,000 people around the world and has 20 industrial sites and 29 R&D centres. Further information is available on the Company’s website www.ivecogroup.com

Media Contacts:
Francesco Polsinelli, Tel: +39 335 1776091
Fabio Lepore, Tel: +39 335 7469007
E-mail: mediarelations@ivecogroup.com

Investor Relations:
Federico Donati, Tel: +39 011 0073539
E-mail: investor.relations@ivecogroup.com

Attachment

• 20231222_PR_Iveco_Group_Buyback

GlobeNewswire Distribution ID 1000905866